Loading clinical trials...
Loading clinical trials...
The investigators will perform a multicenter, 2:1 randomized, double-blinded, placebo-controlled trial of AMR in patients with diarrhea predominant-IBS (IBS-D) diagnosed according to Rome III criteria...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
University of Ulm
Collaborators
NCT06737666 · Diarrhea-predominant Irritable Bowel Syndrome
NCT02612649 · Diarrhea-predominant Irritable Bowel Syndrome
NCT05593367 · Diarrhea-predominant Irritable Bowel Syndrome
NCT05369884 · Non-erosive Reflux Disease, Diarrhea-Predominant Irritable Bowel Syndrome
NCT01414244 · Diarrhea-Predominant Irritable Bowel Syndrome
Helios Klinikum Krefeld
Krefeld
Ulm University Hospital
Ulm
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions